Patents by Inventor Paul A. Knepper

Paul A. Knepper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230270689
    Abstract: Neurodegenerative diseases are treated by the co-administration to a subject of an effective amount of a stilbene, a flavonol, and a TLR4/MD2 receptor antagonist. A preferred stilbene is resveratrol, a preferred flavonol is quercetin, and a preferred TLR4/MD2 receptor antagonist is curcumin.
    Type: Application
    Filed: May 3, 2023
    Publication date: August 31, 2023
    Inventor: Paul A. Knepper
  • Patent number: 11723343
    Abstract: A system for determining the gender and/or fertility status of avian eggs including a sampling apparatus and an electromagnetic radiation transmitter and detector. In certain embodiments, the transmitter operates in the terahertz range. The sampling apparatus can be coupled to an avian egg. The sampling apparatus includes a vacuum source, a gas collection device, and a membrane that can be positioned in the passageway coupling the vacuum source to the gas collection device. The membrane is capable of capturing volatile organic compounds. The sampling apparatus applies a vacuum from the vacuum source to the gas proximate to the avian egg and directs the gas captured from the vicinity of the egg toward the membrane. Subsequently, the membrane is positioned within the electromagnetic radiation emitted by the transmitter, generating a spectrum which can be analyzed to determine whether the egg is fertile or infertile, and if fertile, whether the egg is male or female.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: August 15, 2023
    Assignee: NOVATRANS GROUP S.A.
    Inventors: Paul Knepper, Matthew O'Hayer, Jonathan Hoopes, Eran Gabbai
  • Patent number: 11570971
    Abstract: A system for determining the gender and/or fertility status of avian eggs including a sampling apparatus and an electromagnetic radiation transmitter and detector. In certain embodiments, the transmitter operates in the terahertz range. The sampling apparatus can be coupled to an avian egg. The sampling apparatus includes a vacuum source, a gas collection device, and a membrane that can be positioned in the passageway coupling the vacuum source to the gas collection device. The membrane is capable of capturing volatile organic compounds. The sampling apparatus applies a vacuum from the vacuum source to the gas proximate to the avian egg and directs the gas captured from the vicinity of the egg toward the membrane. Subsequently, the membrane is positioned within the electromagnetic radiation emitted by the transmitter, generating a spectrum which can be analyzed to determine whether the egg is fertile or infertile, and if fertile, whether the egg is male or female.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: February 7, 2023
    Assignee: Novatrans Group S.A.
    Inventors: Paul Knepper, Matthew O'Hayer, Jonathan Hoopes, Eran Gabbai
  • Publication number: 20220175697
    Abstract: Age-related macular degeneration (AMD) is treated by administration of a stilbene, a flavonol, and curcumin or a biologically active curcumin analog to a patient afflicted with AMD.
    Type: Application
    Filed: January 13, 2022
    Publication date: June 9, 2022
    Inventor: Paul A. Knepper
  • Patent number: 11234942
    Abstract: Pharmaceutical compositions containing a stilbene such as resveratrol, a flavonol such as quercetin, and a TLR4/MD2 receptor antagonist such as naltrexone or curcumin inhibit aggregation of superactivated platelets, block activation of the coagulation cascade, and are useful for treating microvascular diseases including neurodegenerative diseases such as Alzheimer's disease and dementia, for treating primary open-angle glaucoma, for reducing scar formation, and like afflictions that involve the coagulation cascade.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: February 1, 2022
    Inventor: Paul A. Knepper
  • Publication number: 20210212297
    Abstract: A system for determining the gender and/or fertility status of avian eggs including a sampling apparatus and an electromagnetic radiation transmitter and detector. In certain embodiments, the transmitter operates in the terahertz range. The sampling apparatus can be coupled to an avian egg. The sampling apparatus includes a vacuum source, a gas collection device, and a membrane that can be positioned in the passageway coupling the vacuum source to the gas collection device. The membrane is capable of capturing volatile organic compounds. The sampling apparatus applies a vacuum from the vacuum source to the gas proximate to the avian egg and directs the gas captured from the vicinity of the egg toward the membrane. Subsequently, the membrane is positioned within the electromagnetic radiation emitted by the transmitter, generating a spectrum which can be analyzed to determine whether the egg is fertile or infertile, and if fertile, whether the egg is male or female.
    Type: Application
    Filed: March 30, 2021
    Publication date: July 15, 2021
    Applicant: NOVATRANS GROUP S.A.
    Inventors: Paul Knepper, Matthew O'Hayer, Jonathan Hoopes, Eran Gabbai
  • Publication number: 20210212296
    Abstract: A system for determining the gender and/or fertility status of avian eggs including a sampling apparatus and an electromagnetic radiation transmitter and detector. In certain embodiments, the transmitter operates in the terahertz range. The sampling apparatus can be coupled to an avian egg. The sampling apparatus includes a vacuum source, a gas collection device, and a membrane that can be positioned in the passageway coupling the vacuum source to the gas collection device. The membrane is capable of capturing volatile organic compounds. The sampling apparatus applies a vacuum from the vacuum source to the gas proximate to the avian egg and directs the gas captured from the vicinity of the egg toward the membrane. Subsequently, the membrane is positioned within the electromagnetic radiation emitted by the transmitter, generating a spectrum which can be analyzed to determine whether the egg is fertile or infertile, and if fertile, whether the egg is male or female.
    Type: Application
    Filed: March 30, 2021
    Publication date: July 15, 2021
    Applicant: NOVATRANS GROUP S.A.
    Inventors: Paul Knepper, Matthew O'Hayer, Jonathan Hoopes, Eran Gabbai
  • Patent number: 11006617
    Abstract: A system for determining the gender and/or fertility status of avian eggs including a sampling apparatus and an electromagnetic radiation transmitter and detector. In certain embodiments, the transmitter operates in the terahertz range. The sampling apparatus can be coupled to an avian egg. The sampling apparatus includes a vacuum source, a gas collection device, and a membrane that can be positioned in the passageway coupling the vacuum source to the gas collection device. The membrane is capable of capturing volatile organic compounds. The sampling apparatus applies a vacuum from the vacuum source to the gas proximate to the avian egg and directs the gas captured from the vicinity of the egg toward the membrane. Subsequently, the membrane is positioned within the electromagnetic radiation emitted by the transmitter, generating a spectrum which can be analyzed to determine whether the egg is fertile or infertile, and if fertile, whether the egg is male or female.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: May 18, 2021
    Assignee: NOVATRANS GROUP S.A.
    Inventors: Paul Knepper, Matthew O'Hayer, Jonathan Hoopes, Eran Gabbai
  • Publication number: 20210106542
    Abstract: Inhibition of aggregation of superactivated platelets, blocking of activation of coagulation cascade, treatment of primary open-angle glaucoma, and treatment of microvascular diseases is effected by co-administration of a stilbene, a flavonol, and a ?-opioid receptor antagonist.
    Type: Application
    Filed: December 22, 2020
    Publication date: April 15, 2021
    Inventor: Paul A. Knepper
  • Publication number: 20190174726
    Abstract: A system for determining the gender and/or fertility status of avian eggs including a sampling apparatus and an electromagnetic radiation transmitter and detector. In certain embodiments, the transmitter operates in the terahertz range. The sampling apparatus can be coupled to an avian egg. The sampling apparatus includes a vacuum source, a gas collection device, and a membrane that can be positioned in the passageway coupling the vacuum source to the gas collection device. The membrane is capable of capturing volatile organic compounds. The sampling apparatus applies a vacuum from the vacuum source to the gas proximate to the avian egg and directs the gas captured from the vicinity of the egg toward the membrane. Subsequently, the membrane is positioned within the electromagnetic radiation emitted by the transmitter, generating a spectrum which can be analyzed to determine whether the egg is fertile or infertile, and if fertile, whether the egg is male or female.
    Type: Application
    Filed: July 31, 2017
    Publication date: June 13, 2019
    Inventors: Paul Knepper, Matthew O'Hayer, Jonathan Hoopes, Eran Gabbai
  • Publication number: 20190175522
    Abstract: Pharmaceutical compositions containing a stilbene such as resveratrol, a flavonol such as quercetin, and a TLR4/MD2 receptor antagonist such as naltrexone or curcumin inhibit aggregation of superactivated platelets, block activation of the coagulation cascade, and are useful for treating microvascular diseases including neurodegenerative diseases such as Alzheimer's disease and dementia, for treating primary open-angle glaucoma, for reducing scar formation, and like afflictions that involve the coagulation cascade.
    Type: Application
    Filed: February 14, 2019
    Publication date: June 13, 2019
    Inventor: Paul A. Knepper
  • Publication number: 20190046466
    Abstract: Pharmaceutical compositions containing a stilbene such as resveratrol, a flavonol such as quercetin, and a ?-opioid receptor antagonist such as naltrexone inhibit aggregation of superactivated platelets, block activation of the coagulation cascade, and are useful for treating microvascular diseases including neurodegenerative diseases such as Alzheimer's disease and dementia, for treating primary open-angle glaucoma, for reducing scar formation, and like afflictions that involve the coagulation cascade.
    Type: Application
    Filed: August 18, 2016
    Publication date: February 14, 2019
    Inventor: Paul A. Knepper
  • Patent number: 7375957
    Abstract: A system for facilitating transport of a computer and monitor as a unit is disclosed, and comprises a computer case having an exterior, a support located on the computer case for supporting the monitor on the computer case, and a binder for removably binding the monitor to the computer case when the monitor is positioned on the support. The system may also include a handle located on the exterior of the computer case for being gripped by a hand of a user.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: May 20, 2008
    Assignee: Gateway Inc.
    Inventor: Paul A. Knepper
  • Publication number: 20080080127
    Abstract: A system for facilitating transport of a computer and monitor as a unit is disclosed, and comprises a computer case having an exterior, a support located on the computer case for supporting the monitor on the computer case, and a binder for removably binding the monitor to the computer case when the monitor is positioned on the support. The system may also include a handle located on the exterior of the computer case for being gripped by a hand of a user.
    Type: Application
    Filed: September 29, 2006
    Publication date: April 3, 2008
    Inventor: Paul A. Knepper
  • Patent number: 4812448
    Abstract: A novel pharmacologic therapy for treatment of idiopathic primary open angle glaucoma, drug-induced glaucoma and elevated intraocular pressure is disclosed. The pharmacologic therapy consists of a novel composition comprised of 17-alpha-methyl-testosterone and a physiologically tolerable carrier. In accordance with a method aspect of this invention, the active ingredient is administered to the eye of a warm blooded animal in such a manner as to maintain physiologic or normal intraocular pressure, or to return elevated intraocular pressure to normal levels. The method aspect of this invention may also be employed to ameliorate drug induced elevated intraocular pressure.
    Type: Grant
    Filed: October 14, 1986
    Date of Patent: March 14, 1989
    Inventor: Paul A. Knepper
  • Patent number: 4617299
    Abstract: A novel pharmacologic therapy for treatment of idiopathic primary open angle glaucoma, drug-induced glaucoma and elevated intraocular pressure is disclosed. The pharmacologic therapy consists of a novel composition comprised of a selected anabolic androgenic compound and a physiologically tolerable carrier. In accordance with a method aspect of this invention, the pharmacologic substance is administered to the eye of a warm blooded animal in such a manner as to maintain physiologic or normal intraocular pressure, or to return elevated intraocular pressure to normal levels. The method aspect of this invention may also be employed to prevent drug induced elevated intraocular pressure.
    Type: Grant
    Filed: October 22, 1984
    Date of Patent: October 14, 1986
    Inventor: Paul A. Knepper